126TiP: An open-label, single-arm, phase Ib exploratory study to evaluate the safety and efficacy of golidocitinib in combination with anti-PD-1 in locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with anti-PD-1 containing regimens

Authors
Category Systematic review
ConferenceEuropean Lung Cancer Congress (ELCC) 2025
Year 2025
This article has no abstract
Epistemonikos ID: 514e95ad8cc538a665ec3d682b0320f8cdd8a153
First added on: Jan 22, 2026